Orbem Raises €55.5M Series B to Scale AI-Powered MRI Technology

Why It Matters

The capital accelerates commercialization of AI‑MRI technology, addressing animal‑welfare regulations and reducing food waste, while opening new revenue streams in agri‑food and health sectors.

Key Takeaways

• €55.5M Series B led by Innovation Industries.
• AI‑MRI scans eggs in under one second.
• Over 170M eggs scanned to date.
• Genus Scale detects egg fertilisation early.
• Funds target U.S. market and produce quality analysis.

Pulse Analysis

Orbem’s platform merges magnetic resonance imaging with machine‑learning algorithms to turn raw biological signals into actionable data at industrial speed. Traditional MRI systems are confined to clinical or research labs because of high cost and slow throughput, but Orbem’s AI layer compresses scan time to fractions of a second and automates interpretation. This technical leap creates a new class of non‑destructive analytics that can be deployed on production lines, unlocking information—such as internal composition or viability—that was previously invisible without destroying the product. Investors see this as a scalable deep‑tech moat with cross‑industry relevance.

The company’s first commercial success, Genus Focus, addresses a long‑standing ethical and regulatory challenge in the European poultry industry: the culling of male chicks. By determining egg sex in under one second, hatcheries can separate males before incubation, reducing waste and complying with emerging bans on chick culling. The follow‑on Genus Scale adds fertilisation assessment, allowing producers to discard non‑viable eggs early and redirect them for food use. Together, these solutions improve yield, lower energy consumption, and enhance supply‑chain transparency, delivering measurable cost savings for large‑scale producers.

The €55.5 million Series B gives Orbem the runway to replicate its European model in the United States, where poultry production is larger and regulatory pressure on animal welfare is mounting. The funding also backs the rollout of non‑destructive quality testing for fruits and vegetables, a market segment eager for technology that can sort produce without bruising. Parallel R&D into healthcare diagnostics leverages the same large‑scale MRI data sets, positioning Orbem to enter precision medicine. If execution matches its technical promise, the company could reshape multiple biological value chains.

Deal Summary

Munich‑based Orbem closed a €55.5 million Series B round led by Innovation Industries, with participation from Supernova Invest and existing backers General Catalyst, 83North, The Venture Collective and Possible Ventures. The funding will fuel US expansion, scale its poultry AI‑MRI solutions and expand into fruit, vegetable and healthcare markets.